The Simply Good Foods Company
$1.10B- Market cap
- $951.84M
- Debt
- +$249.07M
- Cash
- −$98.47M
Capital structure 79% equity / 21% debt · EV / Revenue 0.76x · EV / EBITDA 5.93x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: SMPL stock price vs ZNTL: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ZNTL's multiple
Needs ZNTL P/E.
Implied fair value · at SMPL's multiple
Needs Annual EPS is negative.
Metric by metric
Price unavailable
Where each company leads, and how wide the gap is.
Higher is better
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: SMPL FY 2025 (ended Aug 30, 2025) · ZNTL FY 2024 (ended Dec 31, 2024). Fiscal years are not aligned.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
Market cap plus debt, less cash.
Capital structure 79% equity / 21% debt · EV / Revenue 0.76x · EV / EBITDA 5.93x
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
The Simply Good Foods Company · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Zentalis Pharmaceuticals, Inc. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.14x
0.24x
Net debt / EBITDA
Leverage against operating earnings
0.81x
-0.29x
Cash and equivalents
Liquid reserves on the balance sheet
$98.47M
$33.90M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Mondelez International, Inc.
SMPL vs MDLZ
HERSHEY CO
SMPL vs HSY
Post Holdings, Inc.
SMPL vs POST
HAIN CELESTIAL GROUP INC
SMPL vs HAIN
Arcus Biosciences, Inc.
SMPL vs RCUS
Repare Therapeutics Inc.
SMPL vs RPTX
IDEAYA Biosciences, Inc.
SMPL vs IDYA
Mersana Therapeutics, Inc.
SMPL vs MRSN
EXELIXIS, INC.
SMPL vs EXEL
$249.07M
$82.57M
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.